Alkermes PLC (ALKS): Price to Sales

Corporate company logo of Alkermes PLC (ALKS)

Alkermes plc (ALKS) is implementing "green chemistry" to minimize toxic laboratory emissions. The revenue multiple reflects the market valuation of sales, with 4.50 becoming the new value for this metric. The monopoly potential of neurobiology patents ensures high margins, while a stable staff of leading scientists guarantees the preservation of intellectual capital and the protection of R&D competencies.

Price-to-Revenue Ratio: alkermes.com (ALKS) for 07/04/2022 - 11/13/2026

Analytical breakdowns for Alkermes Inc. (ALKS)

- share price and consensus valuation forecast:
Price Performance Chart alkermes.com|ALKS - Price Target Chart
- stock exchange capitalization data:
Market Value Alkermes Inc.|ALKS - Enterprise Value
- shareholders' equity book value data:
Book Value per Share Alkermes|ALKS - Company Book Value|Market Value to Book Value Ratio alkermes.com|ALKS - Aggregate Company Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Alkermes plc|ALKS - Long-Term Debt to Capital|Current Liabilities to Capital Alkermes Corp|ALKS - Company Debts|Debt to Net Assets Ratio Alkermes Inc.|ALKS - Company Long-Term Debt|Company Current Liabilities Alkermes|Immediate Liquidity alkermes.com
- company profitability and valuation multiples indicators:
ALKS - Company Net Income|Company Profit Forecast Alkermes plc|ALKS - Price to Earnings Ratio|Future Price to Earnings Multiple Alkermes PLC|ALKS - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Alkermes Inc.|ALKS - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Alkermes|ALKS - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months alkermes.com|ALKS - Earnings growth in current year|Earnings growth forecast for next year Alkermes plc
- total revenue and sales volume data:
ALKS - Company Revenue|Company Projected Revenue alkermes.com|ALKS - Price-to-Revenue Ratio|Forward P/S Multiple Alkermes Inc.
Fundamental company analysis:alkermes.com, ALKS
Signature product of Alkermes

Steady demand for Alkermes plc (ALKS) psychiatric medications makes the P/S divergence from its historical average a precise indicator of market distortions relative to actual sales. This metric correlates market capitalization with annual revenue, allowing investors to determine whether the asset's current price is justified by the volume of generated cash flows or if the market is unjustifiably overvaluing the business.

Competitors of Alkermes plc

AVDL (avadel.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio atai Life Sciences ATAI|GH Research plc (GHRS) - Price to Sales|MindMed Inc. - P/S Multiple|CMPS - P/S Multiple|LB Pharmaceuticals Inc (LBRX) - Price-to-Revenue Ratio|DRUG (brightmindsbio.com) - Price-to-Revenue Ratio|Price-to-Revenue Ratio Vanda Pharmaceuticals Inc.|P/S Multiple Cybin Corp|P/S Multiple ANRO|NRXP - Price to Sales|Price-to-Revenue Ratio Cingulate CING|Market Capitalization-to-Revenue Ratio SILO|CPHI - Price-to-Revenue Ratio|clearmindmedicine.com (CMND) - Market Cap to Revenue|PBM: P/S Multiple|Price to Sales SciSparc Corp (SPRC)|Price-to-Revenue Ratio Seelos Therapeutics|Virpax (VRPX) - Price-to-Revenue Coefficient|Market Cap to Revenue KRTX (Karuna Therapeutics, Inc.)